Ivan Moskalev

Mr. Ivan Moskalev


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2025 in Chemistry
Verified
Journal Article
Open access
PDF file
IMIvan Moskalev
Ivan Moskalev
EAEkaterina Aleksandrovna Akishina
Ekaterina Aleksandrovna Akishina
EDE. A. Dikusar
E. A. Dikusar
Olga I. YarovayaOlga I. Yarovaya
Olga I. Yarovaya
Sophia S. BorisevichSophia S. Borisevich
Sophia S. Borisevich
NSNariman F. Salakhutdinov
Nariman F. Salakhutdinov
In 2022, the number of mpox cases spiked worldwide, leading to a surge in scientific research on members of the Orthopoxvirus genus and the discovery of new compounds exhibiting anti-orthopoxvirus activity. This work is devoted to the synthesis of compounds containing an adamantane fragment and the evaluation of their activity against the vaccinia virus, offering a possible mechanism of the antiviral action of the synthesized agents. Among all the studied adamantane derivatives, three compounds (2, 4, and 12) were found to demonstrate the highest antiviral activity, with the most promising compound 2 (N-(adamantan-1-yl)isonicotinamide) having the lowest toxicity level with a selectivity index (SI) of 115. The pharmacophoric profiles of these compounds are similar to the pharmacophoric profile of tecovirimat, an inhibitor of the membrane viral protein p37. Analysis of the results of molecular modeling suggests that the investigated compounds can inhibit the vaccinia virus by suppressing the phospholipase activity of membrane viral protein p37.